Skip to main content
Equibles
SPRO logo

SPRO · Spero Therapeutics, Inc.

Track SPRO — free

Use SPRO with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about SPRO

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.23 -0.01 (-0.81%) At close · Aug 14
Market Cap
$71.63M
Shares
58.23M

Spero Therapeutics, Inc. Earnings Call Transcripts

Every quarterly earnings call for Spero Therapeutics, Inc. (SPRO) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲329.2% $7.30M −$19.40M '21 Q1 21-05-06 ▲198.1% $5.15M −$18.60M '21 Q2 21-08-05 ▼23.3% $3.06M −$22.50M '21 Q3 21-11-10 ▲43.9% $2.74M −$29.30M '21 Q4 22-03-31 ▼71.7% $2.07M −$32.80M '22 Q1 22-05-16 ▼61.3% $1.99M −$28.70M '22 Q2 22-08-10 ▼34.5% $2.01M −$11.70M '22 Q3 22-11-14 ▲1628.9% $47.44M $26.79M '22 Q4 23-01-09 ▲0% $2.07M −$13.30M '23 Q1 23-05-11 ▲36.3% $2.72M −$11.90M '23 Q2 23-08-10 ▲1169.8% $25.47M −$3.20M '23 Q3 23-11-13 ▲55% $73.52M $51.21M '23 Q4 24-03-13 ▲275.4% $10.20M −$17.86M '24 Q2 24-08-05 ▼79.5% $15.04M −$20.89M '24 Q4 25-03-27 ▲39.1% $14.19M −$1.70M '25 Q2 25-08-12 LATEST ▼100% $ −$9.55M '26 Q2 26-08-12
Earnings call
FY26 · Q2
2026-08-12
Spero Therapeutics, Inc. Q2 FY2026 Earnings Call
Revenue
$
▼ 100% YoY
Diluted EPS
$-0.16
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Spero Therapeutics, Inc. Q2 FY2025 Earnings Call
Confident tone Tebipenem HBr oral carbapenem opportunity PIVOT-PO Phase III success GSK partnership and economics
Revenue
$14.19M
▲ 39.1% YoY
Diluted EPS
$-0.03
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-27
Spero Therapeutics, Inc. Q4 FY2024 Earnings Call
Revenue
$15.04M*
▼ 79.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q2
2024-08-05
Spero Therapeutics, Inc. Q2 FY2024 Earnings Call
Positive tone SPR720 for NTM-PD Tebipenem-HBr Phase 3 PIVOT-PO Endpoint definitions and study design
Revenue
$10.20M
▲ 275.4% YoY
Diluted EPS
$-0.33
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-13
Spero Therapeutics, Inc. Q4 FY2023 Earnings Call
Positive tone SPR720 in NTMPD (lead asset) SPR206 IND clearance and funding Tebipenem HBr Phase 3 PIVOT-PO
Revenue
$73.52M*
▲ 55% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-13
Spero Therapeutics, Inc. Q3 FY2023 Earnings Call
Revenue
$25.47M
▲ 1169.8% YoY
Diluted EPS
$-0.06
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
Spero Therapeutics, Inc. Q2 FY2023 Earnings Call
Revenue
$2.72M
▲ 36.3% YoY
Diluted EPS
$-0.23
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Spero Therapeutics, Inc. Q1 FY2023 Earnings Call
Revenue
$2.07M
▲ 0% YoY
Diluted EPS
$-0.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Spero Therapeutics, Inc. Q4 FY2022 Earnings Call
Revenue
$47.44M*
▲ 1628.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-14
Spero Therapeutics, Inc. Q3 FY2022 Earnings Call
Revenue
$2.01M
▼ 34.5% YoY
Diluted EPS
$-0.33
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-10
Spero Therapeutics, Inc. Q2 FY2022 Earnings Call
Revenue
$1.99M
▼ 61.3% YoY
Diluted EPS
$-0.87
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-16
Spero Therapeutics, Inc. Q1 FY2022 Earnings Call
Revenue
$2.07M
▼ 71.7% YoY
Diluted EPS
$-1.01
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-31
Spero Therapeutics, Inc. Q4 FY2021 Earnings Call
Revenue
$2.74M*
▲ 43.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Spero Therapeutics, Inc. Q3 FY2021 Earnings Call
Revenue
$3.06M
▼ 23.3% YoY
Diluted EPS
$-0.70
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Spero Therapeutics, Inc. Q2 FY2021 Earnings Call
Revenue
$5.15M
▲ 198.1% YoY
Diluted EPS
$-0.63
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Spero Therapeutics, Inc. Q1 FY2021 Earnings Call
Revenue
$7.30M
▲ 329.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-11
Spero Therapeutics, Inc. Q4 FY2020 Earnings Call
Revenue
$1.91M*
▲ 174% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Spero Therapeutics, Inc. Q3 FY2020 Earnings Call
Revenue
$4.00M
▼ 14% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Spero Therapeutics, Inc. Q2 FY2020 Earnings Call
Revenue
$1.73M
▼ 19.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-08
Spero Therapeutics, Inc. Q1 FY2020 Earnings Call
Revenue
$1.70M
▼ 78% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–20 of 20 earnings calls
Key facts CIK 1701108 CUSIP 84833T103 13F (30d) 58 filings 58 filers Visit website

Report a Problem

Category
Description
Email (optional, for follow-up)